Fig 1: NQO2-catalyzed reduction of amodiaquine- and carbamazepine-derived quinones. Recombinant NQO1 or NQO2 was incubated for 1 min with purified quinone imines (50 μM) and GSH (50 μM) in absence (filled circles) or presence (open circles) of 250 μM NADPH or NRH. Amodiaquione quinone imine (A and B) and desethylamodiaquine quinoneimine (C and D) are formed by CYP-catalyzed oxidation of amodiaquine, and iminoquinone is a metabolite of carbamazepine (E and F). GSH conjugation is presented relative to the incubation without NQO and cofactor. Data represent the average and range of duplicates.
Fig 2: NQO2-catalyzed reduction of the acetaminophen-derived quinone imine NAPQI (A) and the clozapine-derived nitrenium ion (B). CYP-catalyzed oxidation to quinones and subsequent enzymatic reduction or chemical GSH conjugation occurred simultaneously in a 30 min incubation containing acetaminophen (250 μM) or clozapine (100 μM), human liver microsomes, recombinant NQO2, and GSH (500 μM) in absence (black) or presence (white) of NRH (250 μM). Data are presented relative to the incubation without NQO2 and NRH and represent the average and range of duplicates.
Fig 3: Inhibition of NQO2-mediated quinone reduction by tacrine. Acetaminophen (250 μM, A) was bioactivated by human liver microsomes to NAPQI, which was reduced by recombinant NQO2 in the presence of NRH (250 μM) and GSH (500 μM). Inhibition of NQO2 was shown over a range of tacrine concentrations. Synthetic amodiaquine quinone imine (50 μM, B) was incubated with recombinant NQO2, NRH (250 μM), and GSH (50 μM). Incubations were performed for 30 min (acetaminophen) or 1 min (amodiaquine quionone). NQO2 was pre-incubated with a range of tacrine concentrations before starting the reaction by addition of NADPH (A) or quinone imine (B). Data represents the average and range of duplicates.
Fig 4: Hepatic expression levels of NQO1 (A) and NQO2 (B) in 20 donors. Liver concentrations were determined by analysis of enzyme-specific reaction velocities and comparison with calibration curves made from recombinant enzymes. Cytosolic concentrations are extrapolated to hepatic concentrations using cytosolic liver contents and intracellular hepatocytes volumes. Donors are sorted by NQO2 concentrations. Data represent average and range of duplicates.
Fig 5: NQO2-catalyzed reduction of diclofenac- and mefenamic acid-derived quinones. CYP-catalyzed formation of quinone imines from 4′-hydroxydiclofenac (50 μM) (A), 5-hydroxydiclofenac (50 μM) (B), 4′-hydroxymefenamic acid (250 μM mefenamic acid) (C), or 5-hydroxymefenamic acid (250 μM mefenamic acid) (D) and subsequent enzymatic reduction or chemical GSH conjugation was simultaneous in a 30 min incubation containing human liver microsomes, recombinant NQO2, and GSH (500 μM) in absence (black) or presence (white) of NRH (250 μM). Data represent the sum of GSH conjugates derived from 4′- or 5-hydroxydiclofenac or 4′- or 5-hydroxymefenamic acid and are presented relative to the incubation without NQO2 and NRH. Data represent the average and range of duplicates.
Supplier Page from OriGene Technologies for NQO2 (NM_000904) Human Untagged Clone